<DOC>
	<DOCNO>NCT02865707</DOCNO>
	<brief_summary>Ulcerative colitis ( UC ) relapse chronic intestinal inflammation exist cure , affect 300 per 100.000 Canadians , high prevalence world . This disease lead significant economic burden due frequent hospitalization , continuous use expensive medication prevent flare , work loss . It also significant impact quality life , risk colectomy development colorectal carcinoma . The standard drug therapy expensive potentially toxic , mostly direct chronic inflammatory process . Relatively little known pathogenesis UC . One hypotheses UC result dysbiosis disease-inducing protective intestinal bacteria genetically susceptible host . Non-digestible dietary carbohydrate ( NDC ) stimulate growth protective endogenous intestinal bacteria ferment short-chain fatty acid ( SCFA ) , latter natural anti-inflammatory property , call prebiotics . NDC inexpensive versus standard drug UC easy administer probiotic . The investigator first report oral intake NDC , dietary β-fructans inulin plus fructo-oligosaccharides ( FOS ) , reduce colitis genetically-induced rat colitis model . Both inulin FOS reduce colitis , NDC modify specific luminal microbiota . A small trial mixture NDC patient active UC relapse oral 5-aminosalicylic acid ( 5-ASA ) show dose-dependent clinical response , confirm transnational potential NDC mixture . The investigator propose randomize placebo-controlled trial ass inulin plus FOS also prevent relapse UC patient inactive disease stable maintenance drug . Primary hypothesis inulin plus FOS effective adjunct therapy standard drug maintain clinical remission . The second hypothesis colonic microflora metabolic function , alter inulin plus FOS , , mediate protection relapse UC . The longitudinal design maintenance prevention study serially collect colon biopsy , stool , serum urine within patient relapse ( inflammation ) occur , would enable identify unique change intestinal microbiota , metabolic function also assess effect host-immune response associate remission relapse occur treatment beta-fructans , .</brief_summary>
	<brief_title>Ulcerative Colitis Relapse Prevention Prebiotics</brief_title>
	<detailed_description>Objectives : Based efficacy inulin plus FOS show experimental colitis well ability improve active human UC investigator propose double-blind placebo control study use Synergy1 , 1:1 FOS/ inulin mixture , patient clinical remission UC . The specific aim study follow : 1 . To determine β-fructans effective maintain clinical remission UC patient . 2 . To examine mechanisms action β-fructans intestinal microbiota composition function host immune response patient . It hypothesize β-fructans prolong remission UC patient inactive disease maintain standard drug therapy prebiotics beneficial effect associate enhance colonic energy homeostasis result specific stimulation butyrate- and/ SCFA-producing microorganism combine improved host mucosal energy inflammation regulation . The propose trial Trial Design : A double blind placebo control clinical trial Intervention duration treatment : All patient treatment group receive chicory-derived β-fructans inulin plus FOS ( 1:1 ) ( `` Synergy1 '' ) 6 month . Synergy1 administer 7.5 gram dose twice day pre-packaged powder add meal provide Beneo-Orafti . This 15 gram daily prebiotic dose find effective treat mild moderately active UC investigator 's previous pilot study . Patients placebo group receive non-fermentable maltodextrin similar appearance , dosage frequency β-fructans . Patients complete 6 month treatment period monitor disease relate symptom additional 6 month . Co-Intervention : Participants continue standard maintenance therapy duration trial . Participants ask maintain regular diet . This confirmed subject complete Food Frequency Questionnaire assess dietary intake 0 6 month study , relapse , use online system . Compliance assess count study agent package metabolomic analysis participant serum urine . Specimen Samples : Fecal sample collect fecal calprotectin ( FC ) microbiota analysis 0 , 1 , 3 , 6 12 month , relapse . Colon biopsy collect 15-20 cm anus host mucosal response ( 4 biopsy ) , microbiota study ( 4 biopsy ) histology ( 2 biopsy ) start , 6 month , relapse . Urine blood/serum collect metabolomics analysis 0 , 1 , 3 6 month treatment , relapse . Colonic luminal wash collect start 6 month relapse sigmoidoscopy exam . Sample Size : Ninety patient , 45 arm , need detect difference 30 % proportion UC patient clinical recurrence 6 month power 80 % use two-sided p=0.05 level test . An anticipated dropout rate trial 10 % , base previous maintenance trial , therefore overall sample size trial 100 patient . Outcomes : Primary Outcome : The proportion patient relapse 6 month . Relapse define increase Mayo score 3 endoscopy grade equal 2 , rectal bleeding least 3 day . The relapse rate prebiotic-treated group 6 month compare relapse rate placebo group . Secondary outcome : 1 ) Time relapse . 2 ) Patient compliance tolerability . Compliance assess ratio package ( use ) divide total package dispense 6 month . Tolerability assess validated questionnaire Casellas et al adverse effect bloat flatulence , compliance package , pill count metabolomic analysis 3 6 month , relapse . 3 ) Intestinal inflammation ( measured fecal calprotectin ) baseline month 1 , 3 6 , relapse . 4 ) Microscopic inflammation score ( 0 6 month , relapse ) Basic science parameter : 1 ) Colonic biopsy cytokine measurement , butyrate transporter oxidation pathway Mucin 2 ( MUC2 ) mRNA expression analysis , histological assessment characterization quantification mucosa-associated microbiota ; 2 ) Stool urine assessment fecal calprotectin concentration , luminal microbiota metabolic product use pyrosequencing , quantitative PCR ( qPCR ) gas chromatography ( GC ) nuclear magnetic resonance ( NMR ) ; 3 ) Blood/serum metabolomic analysis GC NMR ; 4 ) colonic luminal waste assess Immunoglobulin G ( IgG ) associate microbiota .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients Ulcerative colitis ( UC ) confirm diagnosis histology endoscopy . Currently clinical remission define total Mayo score ≤ 2 endoscopic score 0 1 ) experience least one flare past 18 month . On stable dos oral 5ASA 2 week and/or stable dos azathioprine and/or antitumor necrosis factor ( antiTNF ) biologics 2 month Colonic involvement &gt; 15 cm anal verge . Ability give valid inform consent For female child bear potential , negative pregnancy test agreement use appropriate birth control study period . Crohn 's disease , indetermined colitis infectious colitis . Active UC , ( total Mayo score ≥ 3 ) Taking prednisone ( steroid equivalent ) within 1 month enrollment Used topical 5ASA steroid within 2 week enrollment Using immunosuppressive treatment 6mercaptopurine methotrexate Used antibiotic within 2 month Used antidiarreal agent previous 3 day Pregnancy lactation Significant chronic disorder severe cardiac disease , significant renal failure , severe pulmonary disease ( need oxygen ) Active gastrointestinal infection Severe psychiatric disorder Not able consent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>prebiotics</keyword>
	<keyword>b-fructans</keyword>
	<keyword>inulin</keyword>
	<keyword>oligofructose</keyword>
	<keyword>intestinal microbiota</keyword>
</DOC>